Lataa...
Reimbursement of Drugs for Rare Diseases through the Public Healthcare System in Canada: Where Are We Now?
INTRODUCTION: Over the past 20 years, the number of therapies developed for rare diseases has rapidly increased. Often, these therapies represent the only active treatment for debilitating and/or life-threatening conditions. However, they create significant challenges for public and private payers....
Tallennettuna:
| Julkaisussa: | Healthc Policy |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Longwoods Publishing
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4748363/ https://ncbi.nlm.nih.gov/pubmed/26571466 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|